Call Options

8 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$6.34 - $9.28 $185,128 - $270,976
-29,200 Reduced 57.82%
21,300 $152,000
Q1 2024

May 15, 2024

BUY
$5.86 - $8.79 $204,514 - $306,770
34,900 Added 223.72%
50,500 $338,000
Q4 2023

Feb 14, 2024

BUY
$4.64 - $9.56 $45,008 - $92,732
9,700 Added 164.41%
15,600 $101,000
Q3 2023

Nov 14, 2023

BUY
$9.4 - $14.04 $940 - $1,404
100 Added 1.72%
5,900 $55,000
Q2 2023

Aug 14, 2023

SELL
$12.96 - $20.93 $11,664 - $18,837
-900 Reduced 13.43%
5,800 $81,000
Q1 2023

May 15, 2023

SELL
$13.48 - $18.79 $12,132 - $16,911
-900 Reduced 11.84%
6,700 $125,000
Q4 2022

Feb 14, 2023

SELL
$12.61 - $18.74 $102,141 - $151,794
-8,100 Reduced 51.59%
7,600 $104,000
Q3 2022

Nov 14, 2022

BUY
$15.33 - $20.36 $85,848 - $114,016
5,600 Added 55.45%
15,700 $300,000

Others Institutions Holding CDMO

About Avid Bioservices, Inc.


  • Ticker CDMO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 62,167,500
  • Market Cap $705M
  • Description
  • Avid Bioservices, Inc., a contract development and manufacturing organization, provides process development and current good manufacturing practices (CGMP) clinical and commercial manufacturing services focused on biopharmaceutical drug substances derived from mammalian cell culture. The company produces monoclonal antibodies and recombinant pro...
More about CDMO
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.